16.98 +0.09 (0.53%)
After hours: 6:10PM EDT
|Bid||16.40 x 4000|
|Ask||17.25 x 1200|
|Day's Range||16.45 - 16.92|
|52 Week Range||15.81 - 32.50|
|PE Ratio (TTM)||16.38|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.22|
Exelixis (EXEL) and partner Ipsen Biopharmaceuticals Canada gain approval for Cabometyx from Health Canada for the treatment of advanced renal cell carcinoma in adult patients.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year.
– Approval based on the improvement in overall survival, progression-free survival and objective response rate for CABOMETYX versus everolimus in the phase 3 pivotal METEOR trial –
NEW YORK, NY / ACCESSWIRE / September 12, 2018 / Major equities closed up on Tuesday, with strong performances from the energy and telecommunications sector, as investors continued to watch the situation ...
Biotech plays are numerous, and Morgan Stanley has a few recommendations to pare and prop a pharma portfolio. The Ratings Analyst Jeffrey Hung initiated coverage of: Alder Biopharmaceuticals Inc (NASDAQ: ...
Today, Exelixis announced that the NCCN (National Comprehensive Cancer Network) had updated its clinical practice guidelines, in which it recommended Cabometyx tablets for the treatment of individuals with advanced renal cell carcinoma irrespective of the patient’s risk status. The NCCN’s clinical practice guidelines for kidney cancer now recommend Cabometyx as the only preferred TKI (tyrosine kinase inhibitor) therapy in treatment-naïve patients who are in the poor to intermediate risk group.
– CABOMETYX recommended for the treatment of previously untreated advanced renal cell carcinoma across all patient risk groups –
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
Today, Tesaro (TSRO) announced the start of the second stage of its JASPER trial. Tesaro is conducting the Phase 2 JASPER trial to evaluate the safety and efficacy of Zejula and an anti-PD-1 antibody combination therapy for the treatment of individuals with NSCLC (non-small cell lung cancer) in a first-line setting. Tesaro decided to go ahead with the trial after Zejula achieved the protocol specified response criteria in the initial group of 16 patients, among whom 14 were evaluable.
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Based on Exelixis Inc’s (NASDAQ:EXEL) earnings update in June 2018, analyst consensus outlook appear cautiously subdued, with earnings expected to grow by 5.2% in the upcoming year relative to theRead More...
NEW YORK, NY / ACCESSWIRE / August 28, 2018 / U.S. markets rose Monday, with the S&P 500 and Nasdaq finishing at new records for the second consecutive session, on news of the new trade agreement with ...
NEW YORK, Aug. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KB ...
On August 22, Exact Sciences (EXAS) is trading at a stock price of $62.95, which represents ~25.78% growth from the close of $50.05 on August 21.
Shares of Exelixis were down nearly 8% despite any news. Seven Stars Cloud Group, Inc. shares were up a little over 52.5% at the close yesterday, on skyrocket volume of a little over 21 million shares. Average trading volume for the stock is only around 277,000 shares.
From an overall perspective, biotech stocks have enjoyed respectable gains this year. The sector exchange-traded fund SPDR S&P Biotech ETF (NYSEARCA:XBI) is up double digits since January’s opening session. That said, the market movement has been anything but steady, with several key players suffering disappointing performances.
Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.